
Andrew Kuykendall
Articles
-
3 weeks ago |
oncologynewscentral.com | Andrew Kuykendall |Robert A. Figlin
This transcript has been lightly edited for style and clarity. Robert A. Figlin, MD: Good afternoon. This is Bob Figlin, the Steven Spielberg Family Chair in Hematology-Oncology and the cancer center director at Cedars-Sinai Cancer in Los Angeles. And I'm absolutely delighted to have Andrew Tucker Kuykendall, who is a member of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa. Andrew, welcome. Andrew Kuykendall, MD: Thank you so much. Dr. Figlin: It's a big day.
-
2 months ago |
ajmc.com | Maggie L. Shaw |Andrew Kuykendall
Bringing this interview with Andrew Kuykendall, MD, clinical researcher at Moffitt Cancer Center, to a close, he addresses safety concerns that have been linked to the injectable hepcidin mimetic rusfertide (Takeda) and its overall impact on patient quality of life. Rusfertide is under investigation for treatment of polycythemia vera, a myeloproliferative neoplasm, in the ongoing phase 3 VERIFY trial (NCT05210790), on which Kuykendall is an investigator.
-
2 months ago |
ajmc.com | Maggie L. Shaw |Andrew Kuykendall
With an expected completion date sometime in June, the phase 3 VERIFY trial (NCT05210790) will soon conclude its investigation of rusfertide (Takeda) as add-on therapy to a patient’s current course of treatment for their polycythemia vera. The investigative agent has already received breakthrough therapy, orphan drug, and fast track designations from the FDA.
-
2 months ago |
ajmc.com | Maggie L. Shaw |Andrew Kuykendall
The investigational rusfertide (Takeda), is currently being evaluated in the phase 3 VERIFY trial (NCT05210790) as an injectable therapeutic to treat polycythemia vera (PV) through achieving and sustaining hematocrit control. This agent has already breakthrough therapy, orphan drug, and fast track designations from the FDA.
-
Mar 19, 2025 |
ajmc.com | Maggie L. Shaw |Andrew Kuykendall
In early March, The American Journal of Managed Care® spoke with Andrew Kuykendall, MD, a clinical researcher at Moffitt Cancer Center who focuses on myeloproliferative neoplasms (MPNs), myelodysplastic syndrome/MPN overlap syndromes, and systemic mastocytosis.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →